| Brooklyn Ctr For Rehab And Residential Health Care | |
| 170 Buffalo Avenue, Brooklyn, New York 11213 | |
| (718) 252-9800 | |
| Name | Brooklyn Ctr For Rehab And Residential Health Care |
|---|---|
| Location | 170 Buffalo Avenue, Brooklyn, New York |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 215 |
| Occupancy Rate | 93.81% |
| Medicare ID (CCN) | 335178 |
| Legal Business Name | Legal Business Name Not Available |
| Ownership Type | For Profit - Partnership |
| NPI Number | 1346376373 |
| Organization Name | PROSPECT PARK NURSING HOME |
| Doing Business As | PROSPECT PARK CARE CENTER, INC. |
| Address | 1455 Coney Island Ave, Brooklyn, NY 11230 |
| Phone Number | 718-252-9800 |
News Archive
Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.
The way in which the sex of an organism is determined may require lifelong maintenance, finds new research from the University of Minnesota.
Mobile health technology can be beneficial in encouraging lifestyle behavior changes and medication adherence among adults ages 60 and older with existing heart disease, yet more research is needed to determine what methods are the most effective.
The eradication of brain tumors in mice following treatment with a novel drug suggests that certain cancers might one day be cured without the use of toxic chemotherapy and radiation.
› Verified 6 days ago
| NPI Number | 1841365509 |
| Organization Name | PROSPECT PARK OPERATING, LLC |
| Doing Business As | BROOKLYN CENTER FOR REHABILITATION AND RESIDENTIAL HEALTH CARE |
| Address | 170 Buffalo Ave, Brooklyn, NY 11213 |
| Phone Number | 718-252-9800 |
News Archive
Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.
The way in which the sex of an organism is determined may require lifelong maintenance, finds new research from the University of Minnesota.
Mobile health technology can be beneficial in encouraging lifestyle behavior changes and medication adherence among adults ages 60 and older with existing heart disease, yet more research is needed to determine what methods are the most effective.
The eradication of brain tumors in mice following treatment with a novel drug suggests that certain cancers might one day be cured without the use of toxic chemotherapy and radiation.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.
The way in which the sex of an organism is determined may require lifelong maintenance, finds new research from the University of Minnesota.
Mobile health technology can be beneficial in encouraging lifestyle behavior changes and medication adherence among adults ages 60 and older with existing heart disease, yet more research is needed to determine what methods are the most effective.
The eradication of brain tumors in mice following treatment with a novel drug suggests that certain cancers might one day be cured without the use of toxic chemotherapy and radiation.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 14.67 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.64 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 38.59 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.51 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 80.61 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.22 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 7.16 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 96.35 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.21 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 10.25 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 2.65 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.25 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.54 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 92.11 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.12 | 82.93 |
News Archive
Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.
The way in which the sex of an organism is determined may require lifelong maintenance, finds new research from the University of Minnesota.
Mobile health technology can be beneficial in encouraging lifestyle behavior changes and medication adherence among adults ages 60 and older with existing heart disease, yet more research is needed to determine what methods are the most effective.
The eradication of brain tumors in mice following treatment with a novel drug suggests that certain cancers might one day be cured without the use of toxic chemotherapy and radiation.
› Verified 6 days ago
Brooklyn Gardens Nursing & Rehabilitation Center Location: 835 Herkimer Street, Brooklyn, New York 11233 Phone: (718) 221-2600 | |
The Heritage Rehabilitation And Health Care Center Location: 5606 15th Ave, Brooklyn, New York 11219 Phone: (718) 851-1000 | |
Spring Creek Rehabilitation & Nursing Care Center Location: 660 Louisiana Ave, Brooklyn, New York 11239 Phone: (718) 669-7100 | |
New Carlton Rehab And Nursing Center, L L C Location: 405 Carlton Ave, Brooklyn, New York 11238 Phone: (718) 789-6262 | |
Cobble Hill Health Center Inc Location: 380 Henry Street, Brooklyn, New York 11201 Phone: (718) 855-6789 |